For women with triple-negative breast cancer (TNBC), adding bevacizumab (Avastin) to standard neoadjuvant chemotherapy was more beneficial for those diagnosed with basal-like tumors compared to those with nonbasal-like tumors. This data was presented at the 2014 San Antonio Breast Cancer Symposium (SABCS), being held Dec. 9-13, 2014 in San Antonio.
On December 3, 2014, the U.S. Food and Drug Administration (FDA) announced the approval of Amgen's immunotherapy drug Blincyto (blinatumomab), a bispecific T-cell engager (BiTE) used to treat patients diagnosed with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia (B-cell ALL).
In May 2012, the United States Preventive Services Task Force (USPSTF) released a recommendation against prostate-specific antigen (PSA) screening for men. The justification for this recommendation was that large randomized trials demonstrated that PSA screening increased detection of prostate cancer, but there was "small to no reduction in prostate cancer-specific mortality."
I had the privilege recently of interviewing Aaron Ciechanover, MD, DSc, one of three co-recipients of the 2004 Nobel Prize in Chemistry for pioneering research that ultimately led to targeted therapy for treatment of cancer.